Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis -

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Ear, nose and throat disorders | Respiratory disorders
Summary
Among 60 adults with symptomatic chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids, the addition of subcutaneous dupilumab to mometasone furoate nasal spray vs mometasone alone reduced endoscopic nasal polyp burden after 16 weeks.
UKMi comment
Dupilumab is an anti-interleukin-4 receptor (IL-4R) and anti-interleukin-13 receptor (IL-13R) human monoclonal antibody currently undergoing phase III investigation for asthma and atopic dermatitis.
Related links: